Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: Results from the ADDITIONS study

Clinical Research in Cardiology

Volumn 101, Issue 5, 2012, Pages 365-373

  Werdan, Karl ^a   Ebelt, Henning ^a   Nuding, Sebastian ^a   Höpfner, Florian ^a   Hack, Guido ^b   Müller Werdan, Ursula ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Servier Deutschland   (Germany)

Author keywords

Angina pectoris; Beta blocker; Coronary artery disease; Heart rate; Ivabradine; Quality of life

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; IVABRADINE; METOPROLOL; NEBIVOLOL; NITRATE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; STABLE ANGINA PECTORIS; TREATMENT DURATION; VISUAL DISORDER;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGINA, STABLE; BENZAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84860835505     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-011-0402-4     Document Type: Article

References (47)

1. Heusch G (2008) Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 153(8):1589-1601 (Pubitemid 351535988)
2. Andrews TC, Fenton T, Toyosaki N, Glasser SP, Young PM, MacCallum G, Gibson RS, Shook TL, Stone PH (1993) Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 88(1):92-100 (Pubitemid 23195437)
3. Fox K, Borer JS, Camm AJ, Danching N, Ferrari R, Lopez-Sendon J, Steg PG, Tardif JC, Tavazzi L, Tendera M (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50(9):823-830 (Pubitemid 47277500)
4. Diaz A, Bourassa MG, Guertin MC, Tardif JC (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26(10):967-974 (Pubitemid 40695027)
5. Graham I, Atar D, Borch-Johnson K, Boysen G, Burell G, Praha R, Dalloneville J, Herrmann-Lingen C, Hoes A (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28(19):2375-2414
6. Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Bohm M (2010) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100(1):11-19
7. Cooney MT, Vartiainen E, Laatikainen T, Joulevi A, Dudina A, Graham I (2010) Simplifying cardiovascular risk estimation using resting heart rate. Eur Heart J 31(17):2141-2147
8. Tardif JC (2009) Heart rate as a treatable cardiovascular risk factor. Br Med Bull 90:71-84
9. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours GLT (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886-894
10. Nationale Versorgungsleitlinie chronische KHK (2006). http:\\www.versorgungsleitlinie.de
11. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB, Jr, Fihn SD, Fraker TD, Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV (2002) ACC/AHA 2002 Guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to update the 1999 Guidelines for the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol:1-125
12. Fox K, Ferrari R, Tendera M, Steg PG, Ford I (2006) Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 152(5):860-866 (Pubitemid 44632933)
13. Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, doubleblind, placebo-controlled trial. Lancet 372(9641):807-816
14. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372(9641):817-821
15. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R (2009) Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 30(19):2337-2345
16. Di Francesco D (1986) Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature 324(6096): 470-473 (Pubitemid 17184165)
17. Di Francesco D, Camm AJ (2004) Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64(16): 1757-1765 (Pubitemid 39215187)
18. Di Francesco D (2005) Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin 21(7):1115-1122 (Pubitemid 41032703)
19. Tardif JC, Ponikowski P, Kahan T, ASSOCIATE I (2009) Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial. Eur Heart J 30:540-548
20. Köster R, Kaehler J, Meinertz T (2009) Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. AHJ 158:e51-e57
21. Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T (2010) Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol 99(10):665-672
22. Koester R, Kaehler J, Meinertz T (2011) Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol 100(2):121-128
23. Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10(7):621-635 (Pubitemid 34056332)
24. Goldsmith KA, Dyer MT, Schofield PM, Buxton MJ, Sharples LD (2009) Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions. Health Qual Life Outcomes 7:96
25. Shu DF, Dong BR, Lin XF, Wu TX, Liu GJ (2011) Long-term beta blockers for stable angina: systematic review and metaanalysis. Eur J Cardiovasc Prev Rehabil [Epub ahead of print]
26. Gandjour A, Lauterbach KW (1999) Review of quality-of-life evaluations in patients with angina pectoris. Pharmacoeconomics 16(2):141-152 (Pubitemid 29450602)
27. Kardas P (2007) Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. Vasc Health Risk Manag 3(2):235-242 (Pubitemid 46860712)
28. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, Held C, Nasman P, Wallen NH (1996) Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 17(1):76-81 (Pubitemid 26111909)
29. Palatini P, Benetos A, Julius S (2006) Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs 66(2):133-144 (Pubitemid 43213899)
30. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095-1108 (Pubitemid 127453463)
31. Tardif JC, Ponikowski P, Kahan T (2009) Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 30(5):540-548
32. Pocock SJ, Elbourne DR (2000) Randomized trials or observational tribulations? N Engl J Med 342(25):1907-1909 (Pubitemid 30419058)
33. Savelieva I, Borer JS, Camm AJ (2007) Low incidence of significant bradycardia during therapy with an I(f) current inhibitor ivabradine: heart rate reduction depends on baseline heart rate. J Am Coll Cardiol 49(9 Suppl A):1007
34. Swedberg K, Komajda M, Böhm M, Borer JS, Dubost-Brama A, Lerebours GLT (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875-885
35. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F (2010) EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 12:1076-1084
36. Gislason GH, Rasmussen V (2006) Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 27: 1153-1158
37. Daly CA, Clemens F, Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM (2010) Inadequate control of heart rate in patients with stable angina: results from the European heart survey. Postgrad Med J 86(1014):212-217
38. Wiest FC, Bryson CL, Burman M, McDonell MB, Henikoff JG, Fihn SD (2004) Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting. Am J Med 117(4):234-241 (Pubitemid 39092716)
39. Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R (2011) Efficacy of ivabradine in combination with betablocker versus uptitration of beta-blocker in patients with stable angina. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy. doi: 10.1007/s10557-011-6327-3
40. Sy RW, Freedman SB (2011) Beta-blocker dose up-titration or addition of ivabradine in stable angina: more is not necessarily better : editorial to: "Efficacy of ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina" by E. Amosova et al. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy. doi:10.1007/s10557-011-6340-6
41. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A (2004) Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 308(1):236-240 (Pubitemid 38090723)
42. Goldsmith KA, Dyer MT, Buxton MJ, Sharples LD (2010) Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease. Health Qual Life Outcomes 8:54
43. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ (2010) A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes 8:13
44. Dougherty CM, Dewhurst T, Nichol WP, Spertus J (1998) Comparison of three quality of life instruments in stable angina pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF-36), and Quality of Life Index-Cardiac Version III. J Clin Epidemiol 51(7):569-575 (Pubitemid 28376965)
45. Longworth L, Buxton MJ, Sculpher M, Smith DH (2005) Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ 6(4):347-353 (Pubitemid 41779933)
46. Fletcher A, McLoone P, Bulpitt C (1988) Quality of life on angina therapy: a randomised controlled trial of transdermal glyceryl trinitrate against placebo. Lancet 2(8601):4-8 pii: S0140-6736(88)92942-X
47. Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32(19): 2395-2404. doi:10.1093/eurheartj/ehr343